Chiome Bioscience Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
4583
- Investments
-
4
- Share Price
-
$0.89
- (As of Thursday Closing)
Chiome Bioscience General Information
Description
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.
Contact Information
- Tokyo Honcho Third Street No. 12
- Number 1 Sumitomo Fudosan Nishi building Building No. 6, Shibuya-ku
- Tokyo, 151-0071
- Japan
Chiome Bioscience Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.89 | $0.90 | $0.78 - $1.95 | $46.5M | 51.4M | 449K | -$0.17 |
Chiome Bioscience Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 42,993 | 52,127 | 51,577 | 45,477 |
| Revenue | 5,192 | 4,800 | 6,492 | 4,503 |
| EBITDA | (9,398) | (13,315) | (12,042) | |
| Net Income | (8,163) | (9,457) | (13,476) | (12,116) |
| Total Assets | 11,737 | 16,897 | 20,330 | 33,884 |
| Total Debt | 2,117 | 1,403 | 1,590 | 1,745 |
Chiome Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chiome Bioscience Patents
Chiome Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022271741-A1 | Purification method of antibody composition | Pending | 10-May-2021 | ||
| CA-3219950-A1 | Purification method of antibody composition | Pending | 10-May-2021 | ||
| AU-2021355919-A1 | Medicine for treating cancer | Pending | 05-Oct-2020 | 0000000000 | |
| CA-3198077-A1 | Medicine for treating cancer | Pending | 05-Oct-2020 | 0000000000 | |
| EP-4226945-A1 | Medicine for treating cancer | Pending | 05-Oct-2020 | A61K31/506 |
Chiome Bioscience Executive Team (5)
Chiome Bioscience Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Akira Furuya | Self | Board Member | 000 0000 |
| Haruhisa Kubota | Self | Board Member | 000 0000 |
| Yasuhiro Tsuji Ph.D | Chiome Bioscience | Audit & Supervisory Board Member | 000 0000 |
Chiome Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Chiome Bioscience Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Chiome Bioscience Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biotechnol | 01-Dec-2018 | 0000000000 | 00.000 | Biotechnology | |
| EVEC | 30-Mar-2016 | 00000 0000 | 00000 | Drug Discovery | |
| LivTech | 13-Mar-2015 | 000000000 | Biotechnology | ||
| LivTech | 25-Dec-2013 | Merger/Acquisition | 00000 | Biotechnology |
Chiome Bioscience ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Laboratory Equipment and Services
Subindustry
Rank
Percentile
